Efficacy of Chlorhexidine 0/12% and 0/2 % Povidone-iodine mouth rinse on clinical characteristics of patients with COVID-19

Phase 2

Recruiting

• Conditions: COVID-19 associated severe respiratory syndrome.; SARS-CoV-2; U07.1

• Registration Number: IRCT20200527047581N2
• Lead Sponsor: Kashan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 April 2021

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

possibility of involving to COVID-19
PaO2/FiO2 < 300 mm Hg or SpO2 < 93% in air ambient or need to oxygen supplementary for SpO2 in range of 94-98% or lung infiltration > 50%
consciousness of patient and to be able to complete letter of satisfaction
minimum 18 years old

Exclusion Criteria

Pregnancy patient
Immunodeficiency such as patient with Severe combined immune deficiency and HIV
Allergy to mouth rinse
Immunosuppressant drug consumer such as transplantation recipient
Dissatisfaction with participating in the study

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Xerostomia. Timepoint: Daily during first day of hospitalization until 28 days. Method of measurement: percent (has/has not).;Duration of hospitalization. Timepoint: End of study. Method of measurement: Calculation.;Change of Taste sense. Timepoint: Daily during first day of hospitalization until 28days. Method of measurement: percent (has/has not).;New oral erythematous lesion. Timepoint: Daily during first day of hospitalization until 28 days. Method of measurement: percent (has/has not).;New oral ulcer. Timepoint: Daily during first day of hospitalization until 28 days. Method of measurement: percent (has/has not ).